This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/ELVN/capital-change-brief"
Use Arkolith's capital_change_brief for ELVN. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | $312.0M | 8.0M | —Held | Q1 2026 | |
| 2 | FMR LLC | $267.7M | 6.8M | ▼−3.9% Reduced · −278K sh | Q1 2026 | |
| 3 | Polar Capital Holdings Plc | $198.6M | 5.1M | ▲+44% Added · +1.6M sh | Q1 2026 | |
| 4 | BlackRock, Inc. | $144.4M | 3.7M | ▲+2.0% Added · +71K sh | Q1 2026 | |
| 5 | Commodore Capital LP | $128.4M | 3.3M | ▼−30% Reduced · −1.4M sh | Q1 2026 | |
| 6 | Vestal Point Capital, LP | $127.4M | 3.3M | ▼−15% Reduced · −580K sh | Q1 2026 | |
| 7 | Bellevue Group AG | $91.0M | 2.3M | ▲New +2.3M sh | Q1 2026 | |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | $85.0M | 2.2M | ▲New +2.2M sh | Q1 2026 | |
| 9 | Fairmount Funds Management LLC | $72.7M | 1.9M | ▼−50% Reduced · −1.9M sh | Q1 2026 | |
| 10 | CITADEL ADVISORS LLC | $68.4M | 1.7M | ▲+22% Added · +320K sh | Q1 2026 | |
| 11 | Venrock Adviser, LLC | $67.7M | 1.7M | ▼−46% Reduced · −1.5M sh | Q1 2026 | |
| 12 | Novo Holdings A/S | $50.2M | 1.3M | ▼−14% Reduced · −200K sh | Q1 2026 | |
| 13 | STATE STREET CORP | $42.8M | 1.1M | ▲+3.6% Added · +38K sh | Q1 2026 | |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | $41.8M | 1.1M | ▲+1.7% Added · +18K sh | Q1 2026 | |
| 15 | Pictet Asset Management Holding SA | $36.4M | 930K | ▼−29% Reduced · −374K sh | Q1 2026 | |
| 16 | BAKER BROS. ADVISORS LP | $35.5M | 905K | ▲+234% Added · +634K sh | Q1 2026 | |
| 17 | Rock Springs Capital Management LP | $32.4M | 827K | ▲+3.5% Added · +28K sh | Q1 2026 | |
| 18 | ALLIANCEBERNSTEIN L.P. | Withheld | 772K | ▲21× Added · +735K sh | Q1 2026 | |
| 19 | Siren, L.L.C. | $29.3M | 746K | ▲New +746K sh | Q1 2026 | |
| 20 | DIMENSIONAL FUND ADVISORS LP | $26.7M | 682K | ▲+71% Added · +283K sh | Q1 2026 | |
| 21 | First Turn Management, LLC | $24.5M | 624K | ▲New +624K sh | Q1 2026 | |
| 22 | Candriam S.C.A. | $23.3M | 594K | ▲+31% Added · +141K sh | Q1 2026 | |
| 23 | Affinity Asset Advisors, LLC | $23.0M | 587K | ▲New +587K sh | Q1 2026 | |
| 24 | Logos Global Management LP | $21.2M | 540K | ▲+59% Added · +200K sh | Q1 2026 | |
| 25 | MORGAN STANLEY | $20.3M | 519K | ▲+26% Added · +107K sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Jul 6, 2026 | Kunkel Lori Anne | Director | Sell (S) | 4K | $205K |
| Jul 6, 2026 | Kunkel Lori Anne | Director | Sell (S) | 6K | $299K |
| Jun 22, 2026 | ORBIMED ADVISORS LLC | 10% Owner | Sell (S) | 25K | $1.1M |
| Jun 22, 2026 | ORBIMED ADVISORS LLC | 10% Owner | Sell (S) | 1K | $66K |
| Jun 22, 2026 | ORBIMED ADVISORS LLC | 10% Owner | Sell (S) | 787K | $35.7M |
| Jun 22, 2026 | ORBIMED ADVISORS LLC | 10% Owner | Sell (S) | 47K | $2.1M |
| Jun 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Option exercise (M) | 6K | $15K |
| Jun 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell (S) | 1K | $59K |
| Jun 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell (S) | 3K | $149K |
| Jun 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell (S) | 1K | $55K |
| Jun 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Option exercise (M) | 6K | $0 |
| Jun 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Option exercise (M) | 5K | $12K |
| Company | Co-held by | Combined value |
|---|---|---|
| XENON PHARMACEUTICALS INCXENE | 39 funds | $847.4M |
| ELI LILLY & COLLY | 38 funds | $4.9B |
| BOSTON SCIENTIFIC CORPBSX | 38 funds | $1.4B |
| OLEMA PHARMACEUTICALS INCOLMA | 38 funds | $211.5M |
| NVIDIA CORPNVDA | 37 funds | $26.9B |
| MICROSOFT CORPMSFT | 37 funds | $16.3B |
| META PLATFORMS INC-CLASS AMETA | 37 funds | $8.2B |
| DANAHER CORPDHR | 37 funds | $1.2B |
| COGENT BIOSCIENCES INCCOGT | 37 funds | $586.6M |
| TERNS PHARMACEUTICALS INC430 | 37 funds | $401.4M |
| NEUROCRINE BIOSCIENCES INCNBIX | 37 funds | $369.2M |
| DYNE THERAPEUTICS INCDYN | 37 funds | $302.6M |
Ranked by how many of ELVN's institutional holders also hold each name, a cross-fund conviction signal. Via the MCP server (ticker.co_held).
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for ELVN. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes. Every panel above is one call to the Arkolith API & MCP server.